2つ以上の標準的な治療が無効又は治療後に再発した、大細胞型B細胞リンパ腫又は濾胞性リンパ腫に対するエプコリタマブの費用対効果評価
Read via the Internet
Begin reading now
NDL Digital Collections
Bibliographic Record
You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.
- Material Type
- 記事
- Author/Editor
- 柏宗伸此村恵子森脇健介小嶋智美前田知美白岩健下妻晃二郎福田敬
- Publication, Distribution, etc.
- Publication Date
- 2025
- Publication Date (W3CDTF)
- 2025
- Alternative Title
- Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
- Periodical title
- Academic technology assessment group (ATAG) reports
- No. or year of volume/issue
- 3(3)
- Volume
- 3(3)